Clinical trials: Cancer, Advanced Solid Tumors
Advanced Solid Tumors
An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors
This study consists of two Parts. Part A (Food Effect Study) and Part B (Determination of Maximum Tolerated Dose [MTD] for twice daily [BID] Dosing).Part A will be initiated first, and Part B will be initiated after the PK…
- Trial name
- NCT01773421
- Testing
- E7820
- Where
- 6 sites in Netherlands, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Eisai Inc.
Advanced Breast Cancer, HER2/Neu Negative
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or tumor genomic alterations.
- Conditions
- Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer
- Trial name
- NCT02401347
- Testing
- Talazoparib Tosylate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Melinda Telli
Neoplasm Metastasis
A Study of LY2940680 in Japanese Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of LY2940680 up to the global recommended dose in Japanese participants with advanced solid cancers.
- Trial name
- NCT01919398
- Testing
- LY2940680
- Where
- 2 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Eli Lilly and Company
Neoplasms
Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule
This is a three stage, open label, randomized-sequence, single-crossover Phase 1 study to evaluate the relative bioavailability (BA) and Bioequivalence (BE) of niraparib administered as a tablet formulation compared to the…
- Trial name
- NCT03329001
- Testing
- Niraparib Tablet, Niraparib Capsule
- Where
- 16 sites in United States
- Volunteers
- 236 people
- Sponsor
- Tesaro, Inc.
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02898207
- Testing
- Olaparib, Onalespib
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Relapsed/Refractory Lymphoma
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
This study will assess the effect of multi-dose administration of itraconazole on the single-dose pharmacokinetics (PK) of alisertib.
- Trial name
- NCT02259010
- Testing
- Alisertib, Itraconazole
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Neoplasms
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 therapy in terms of drug-related adverse events when combined with a platinum therapy (cisplatin or carboplatin).
- Trial name
- NCT00969761
- Testing
- BI-6727, BI 6727
- Where
- 2 sites in Belgium
- Volunteers
- 61 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor, Advanced Cancer
Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies
The main objective of this study is to determine the maximum tolerated dose (MTD) of Oratecan in combination with capecitabine
- Trial name
- NCT01463982
- Testing
- Oratecan and Capecitabine
- Where
- South Korea
- Volunteers
- 21 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors
This was a multi-center, open-label, phase Ib/II study. The aim of the phase Ib part was to estimate the MTD(s) and/or identify the recommended phase II dose(s) (RP2Ds) for the combination of BYL719 and AMG 479 (ganitumab)…
- Trial name
- NCT01708161
- Testing
- BYL719, AMG 479
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms, Tumor
A Study of IMC-TR1 in Participants With Advanced Solid Tumors
A study to evaluate the safety and tolerability of anti-TGFβRII monoclonal antibody (IMC-TR1) in participants with advanced solid tumors, as well as gather evidence of anti-tumor activity.
- Trial name
- NCT01646203
- Testing
- IMC-TR1
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Eli Lilly and Company
Solid Tumor
Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)
This is planned to be a 5-part dose-escalation study to determine the safety and tolerability of MK-4166 monotherapy and MK-4166 plus pembrolizumab combination therapy, and to establish the maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT02132754
- Testing
- MK-4166, Pembrolizumab
- Volunteers
- 116 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors, Lymphoma
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
The purpose of this study is to assess the drug-drug interaction (DDI) of either esomeprazole or rifampin on the single-dose PK of alisertib, and to complete an intensive QT study of single and multiple-dose alisertib.
- Trial name
- NCT01844583
- Testing
- Alisertib, Esomeprazole, Rifampin
- Where
- 7 sites in United States
- Volunteers
- 55 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Cervical Cancer
A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)
This is a Phase 1/2, open-label study of zalifrelimab (AGEN1884) in combination with balstilimab (AGEN2034) in participants with locally advanced, recurrent and/or metastatic solid tumors including cervical cancer.
- Trial name
- NCT03495882
- Testing
- Zalifrelimab, Balstilimab
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 175 people
- Sponsor
- Agenus Inc.
Advanced Cancer
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
- Trial name
- NCT03369223
- Testing
- BMS-986249, Nivolumab, Ipilimumab
- Where
- 45 sites in United States, Argentina and 9 more
- Volunteers
- 356 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer
This is a world wide phase 1/2, open-label, study of neratinib in combination with capecitabine, conducted in 2 parts. In Part 1, 3 to 9 subjects with solid tumors will be enrolled in each dose group of the combination of…
- Trial name
- NCT00741260
- Testing
- Neratinib, Capecitabine
- Where
- 37 sites in United States, Australia and 9 more
- Volunteers
- 105 people
- Sponsor
- Puma Biotechnology, Inc.
Solid Tumor, Kidney Cancer
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
This research study is evaluating the combination of pazopanib and everolimus in patients that have a malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no…
- Trial name
- NCT01184326
- Testing
- pazopanib, everolimus
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Neoplasms
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors
A dose escalation study to determine the safety and maximum tolerated dose (MTD) of IMC-3C5 in subjects with advanced solid tumors that are refractory to standard therapy or for which no standard therapy is available.
- Trial name
- NCT01288989
- Testing
- IMC-3C5
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with advanced solid tumors with fibroblast growth factor receptor (FGFR) alterations…
- Trial name
- RAGNAR (NCT04083976)
- Testing
- Erdafitinib
- Where
- 179 sites in United States, Argentina and 13 more
- Volunteers
- 316 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumors
Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)
This is a Phase I/II multicenter, first-in-human open-label, dose escalation study to evaluate the safety, tolerability, and anti-tumor activity of intratumoral (IT)/intralesional (IL) injections of MK-4621 (RGT100) in adult…
- Trial name
- NCT03065023
- Testing
- MK-4621
- Where
- 6 sites in Germany, Spain and 1 more
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer
Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)
The purpose of this study is to determine whether food has any effect on a single dose of Cediranib (AZD2171, Recentin™)followed by an assessment of the safety and tolerability of fixed daily dosing in comparison to varying dose…
- Trial name
- NCT00306891
- Testing
- Cediranib, Cediranib 30 - 90 mg
- Where
- 4 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- AstraZeneca